Open Orphan #ORPH – £7.5m Human Challenge Study Contract March 26, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has entered into a contract with a  biotechnology company to run a human viral challenge study for a respiratory syncytial virus (“RSV”) prophylactic and treatment.   This US biotechnology company is developing a product for the prevention and…

Continue reading